Objective-To assess the financial implications of antitachycardia pacing in patients with frequent supraventricular tachycardia.
patients, and pain over the pacemaker required its resiting in two. Two patients have had one admission each for tachycardia. Six patients remain on antiarrhythmic drugs. Costs were calculated including value added tax, capital charges, and allocated overheads. The cost a year before pacing was £1174 including drug costs, clinic visits, and hospital admissions. The mean cost of pacemaker implantation was £3364 22, including the pacemaker and lead, admission and procedure, readmissions and first pacing check. Subsequent annual follow up cost was £73f72 including annual clinic visits and drug costs. The cost of pacing is £4241 whereas medical management costs £7044 assuming pacemaker life of six years: with a 10 year life the cost is £4537 compared with £11 740: with a 12 year life the cost is £4685 compared with £14 088.
Conclusion-The excess cost of implantation of an antitachycardia pacemaker is minimal in patients with frequent supraventricular tachycardia despite drug treatment and is justified by excellent control of symptoms and reduction of drug use and hospital admissions.
(Br Heart 7 1993; 69:272-275) Antitachycardia pacing has been established as an effective means of controlling symptoms in patients with recurrent supraventricular tachycardia, especially atrioventricular nodal tachycardia. 1-The cost of this method of treatment has always been assumed to be high due to the cost of the pacemakers used.
The aim of this study was to assess the cost of antitachycardia pacing in relation to hospital admissions, outpatient appointments, and drug use. The effect on demands on the general practitioner service and employment was also sought.
The use of radiofrequency catheter ablation of fast or slow pathways within the atrioventricular node provides an alternative treatment, which may be even more attractive as it can cure the patient.48 The long-term implications of atrioventricular nodal modification, however, are unknown and fear of late atrioventricular block or ventricular arrhythmias may limit their widespread use until long-term follow up is available.
Patients and methods
The first 25 consecutive patients who had Intertach pacemakers implanted for the control of recurrent supraventricular tachycardias at this hospital were studied. Their age (mean (range)) was 47 (22-72) years and 20 were women. The arrhythmia substrate was atrioventricular nodal tachycardia in 22 patients, atrioventricular tachycardia with concealed accessory pathways in two patients, and the Wolff-Parkinson-White syndrome in one patient. The patients had failed a mean 4-9 (range 0 to 8) antiarrhythmic drug trials over a mean symptomatic period of 13-9 years (range 2 months-54 years). The The mean cost of implantation of the pacemakers with a mean inpatient stay of 2-8 (range 2-7) bed days was £490'50 and the Intertach pacemaker and lead cost £2839 00. On follow up, 13 of the patients were admitted for a total of 64 days, three for supraventricular tachcardia and 10 for wound related problems. Three patients required repositioning of the pacemaker under general anaesthetic. The patient with Wolff-ParkinsonWhite syndrome underwent surgical ablation of her accessory pathway. The mean cost of the stay in hospital was £398 for each patient in the total study group. The initial and subsequent hospital admissions were regarded as non-recurring expenses. Six patients remained on antiarrhythmic drugs at a mean cost for the group of £39 for each patient every year, and an annual outpatient visit was calculated at £34'72 a year, with one extra visit at one month in the first year. The likely life of a pacemaker was calculated by Intermedics to be 12 years. Before implantation nine patients were in full time work, one was in part time work, two were retired, three were not in work and 10 were housewives. After implantation the only changes were the part time worker and one of those not in work who became full time workers. patients (three after failed slow pathway ablation in the same procedure) with a mean time of operation of 165 minutes. A permanent pacemaker was implanted in three patients for complete heart block (average unit cost of DDD pacemaker at Freeman Hospital was £1 811). One patient with complete heart block already had a pacemaker for sick sinus syndrome. They were successful with slow pathway ablation in 32 of 35 patients, two (one at a separate procedure) of whom had successful fast pathway ablation, but a slow tachycardia remained. Mean time of operation was 151 minutes. We assumed five bed nights for the fast pathway ablation (longer because of the risk of late complete heart block) and four bed nights for slow pathway ablation, a total of two follow up clinics and annual pacemaker checks for four patients. Table 4 shows costs. Tables 4 and 5 show the cumulative cost of continued drug treatment compared with pacemaker implantation and subsequent follow up. The assumed medical costs are almost equal to the pacemaker costs at six years but are much more at 10 and 12 years. Longevity of a pacemaker with OAOT mode ranges from 12-2 to 19-8 years (table 1) . The actual medical costs are nearly double the pacemaker costs at six years and some three times the costs at 12 years. Table 4 shows the comparison of antitachycardia pacing with medical treatment and catheter ablation. Selective atrioventricular nodal pathway ablation was the cheapest method and was even cheaper if costs of a diagnostic electrophysiological study was added to the cost of a pacemaker (as was done at the time of ablation by Jazayeri and colleagues).7 Information on the number of consultations for any reason was received from 14 general practitioners. In nine the number of consultations had fallen, in one it had stayed the same and in four there had been an increase in consultations. The mean (SD) number of consultations in the year before implantation was 10-7 (7 2) and 8-0 (6 5) in the year after implantation (p = 0 045, two tailed t test).
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Discussion
The major difficulty in justifying high technology medicine is that the marginal costs seem much greater than those of conservative treatment. This is because it is easier to calculate the cost of a single procedure, with an expensive piece of equipment, than it is to calculate the continuing costs of conservative, usually drug based, treatment. These data show that implantation of an expensive antitachycardia pacemaker may actually save money after six years and these can be appreciable at the pacemaker's expected life of 12 years. This saving is purely in terms of hospital costs and ignores the benefits in quality of life and employment, or the effect of demands on the family doctor, although all of these seem to be improved after implantation.
In making these calculations it has been necessary to make assumptions. 
